European Central Bank President Mario Draghi defended the tools that the organization has available.Europe Newsread more
According to China's top economic planning body, some local companies are cutting back on their efforts to hire new university graduates.China Economyread more
German Chancellor Angela Merkel has presided over a tumultuous recent period, which for many, has left Europe on the brink.Commentaryread more
Tensions between China and the U.S. are threatening to slow global trade further, threatening some Asian economies.Asia Economyread more
U.S. President Donald Trump's former campaign chairman Paul Manafort was transferred to a detention facility in Manhattan on Monday ahead of an expected arraignment on state...White Houseread more
Airbus recorded orders and options for 123 planes, according to the aviation consulting firm IBA.iQ.Paris Air Showread more
Markets in Asia were mostly higher on Tuesday as investors awaited the start of a closely-watched meeting by the U.S. Federal Reserve, set to kick off later stateside.Asia Marketsread more
Wall Street analysts think Facebook's cryptocurrency payments project will give the company a big boost.Marketsread more
Chinese President Xi Jinping will travel to North Korea this week for a two-day visit, ahead of a possible meeting between Xi and President Donald Trump at next week's G-20...Politicsread more
The Pentagon said that the crew of one of the tankers, the Japanese Kokuka Courageous, found an unexploded limpet mine on its hull following an initial explosion.Politicsread more
China's Alibaba Group on Tuesday said its chief financial officer, Maggie Wu, will oversee the firm's strategic acquisitions and investments unit, as part of a business and...Technologyread more
An advisory panel to the U.S. Food and Drug Administration on Thursday voted against approving Alkermes' treatment for depression in patients with an inadequate response to standard antidepressant therapies.
The decision comes two days after FDA staff reviewers flagged abuse potential for the opioid-based depression treatment and raised questions on its efficacy.
"I don't feel the evidence that was presented was substantial to show that there was efficacy ... I'm not convinced there is a big enough treatment effect to make a clinical difference," said Terri Warholak, a panel member.
The panel voted 21-2 against the drug, ALKS 5461, a once-daily pill combining samidorphan and buprenorphine developed as an add-on treatment for major depressive disorder (MDD), saying the data did not support a favorable benefit-risk profile.
ALKS 5461 is designed to rebalance brain function that becomes dysregulated in the state of depression and was seen as a driver of future revenue for the Dublin-based drugmaker.
FDA staffers in the review on Tuesday also questioned the non-availability of trial data on the effects of the treatment on unborn infants when the treatment was administered to pregnant women.
"We don't know what the mechanism of action is ... and the likelihood of dependence and withdrawal," said Jane Acri, also a panel member.
"I think it's a very vulnerable population at risk for drug dependence in the first place."
The FDA, which is slated to announce its final decision on Alkermes' drug by Jan. 31, 2019, is not mandated to follow the recommendation of the panel, but generally does.
MDD affects about 16.2 million people in the United States, of which nearly two-thirds do not respond to currently approved therapies, highlighting the need for new therapies with novel mechanisms of action to treat the disorder.
To date, only three antipsychotic drugs have been approved as add-on treatments for MDD. Alkermes' treatment would be the first opioid-based product for depression, if approved.
There are currently very few treatments for depression.